[go: up one dir, main page]

MX2018012319A - Anticuerpos biespecificos contra el receptor de fc gamma cd25 para la reduccion de celulas especificas de tumores. - Google Patents

Anticuerpos biespecificos contra el receptor de fc gamma cd25 para la reduccion de celulas especificas de tumores.

Info

Publication number
MX2018012319A
MX2018012319A MX2018012319A MX2018012319A MX2018012319A MX 2018012319 A MX2018012319 A MX 2018012319A MX 2018012319 A MX2018012319 A MX 2018012319A MX 2018012319 A MX2018012319 A MX 2018012319A MX 2018012319 A MX2018012319 A MX 2018012319A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
specific cell
tumor specific
cell depletion
gamma receptor
Prior art date
Application number
MX2018012319A
Other languages
English (en)
Inventor
PEGGS Karl
Quezada Sergio
Vargas Fred
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MX2018012319A publication Critical patent/MX2018012319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción hace referencia a un método para el tratamiento de un tumor sólido, donde dicho método implica el uso de un anticuerpo contra CD25. En particular, el anticuerpo contra CD25 se optimiza para la reducción de linfocitos T reguladores (Treg) dentro de tumores. La presente invención proporciona también anticuerpos anti-CD25 novedosos y su combinación con otros fármacos contra el cáncer, tales como inhibidores de puntos de control del sistema inmunitario, compuestos que se dirigen a antígenos contra el cáncer o el receptor de Fc inhibidor FcyRllb (CD32b).
MX2018012319A 2016-04-07 2017-03-17 Anticuerpos biespecificos contra el receptor de fc gamma cd25 para la reduccion de celulas especificas de tumores. MX2018012319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201605947 2016-04-07
PCT/EP2017/056469 WO2017174331A1 (en) 2016-04-07 2017-03-17 Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion

Publications (1)

Publication Number Publication Date
MX2018012319A true MX2018012319A (es) 2019-06-06

Family

ID=58358618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012319A MX2018012319A (es) 2016-04-07 2017-03-17 Anticuerpos biespecificos contra el receptor de fc gamma cd25 para la reduccion de celulas especificas de tumores.

Country Status (15)

Country Link
US (2) US20190135925A1 (es)
EP (1) EP3440109B1 (es)
JP (1) JP7325959B2 (es)
KR (2) KR20190017735A (es)
CN (1) CN109476739A (es)
AU (1) AU2017247880B2 (es)
BR (1) BR112018070636A2 (es)
CA (1) CA3020204A1 (es)
CL (2) CL2018002828A1 (es)
ES (1) ES3046543T3 (es)
IL (1) IL262129B2 (es)
MX (1) MX2018012319A (es)
PL (1) PL3440109T3 (es)
RU (1) RU2759970C2 (es)
WO (1) WO2017174331A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
PL3440109T3 (pl) 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
AU2019207767B2 (en) * 2018-01-10 2025-09-18 Bioinvent International Ab Novel combination and use of antibodies
WO2019160970A1 (en) * 2018-02-13 2019-08-22 Precision Biologics, Inc. Methods and compositions for targeting treg cells
SG11202008784RA (en) * 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
EP3566718A1 (en) * 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
US20220213225A1 (en) * 2018-07-30 2022-07-07 Invenra Inc. Multispecific treg binding molecules
CN113272330B (zh) * 2019-03-02 2024-07-26 南通壹宸生物医药科技有限公司 一种双特异抗体
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
US20230192900A1 (en) * 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
WO2021228218A1 (zh) 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
CA3201423A1 (en) * 2020-11-13 2022-05-19 Ibio, Inc. Cd25 antibodies
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023031403A1 (en) 2021-09-02 2023-03-09 F. Hoffmann-La Roche Ag Antibodies for the treatment of aml
TW202336033A (zh) * 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
US20250257141A1 (en) 2022-04-26 2025-08-14 Hoffmann-La Roche Inc. Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024151091A1 (ko) * 2023-01-11 2024-07-18 한국과학기술원 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물
EP4662238A1 (en) 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof
IL320593A (en) 2023-03-29 2025-07-01 Daiichi Sankyo Co Ltd Anti-CD25 antibody and anti-CD25 antibody conjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505991C (en) * 2002-11-15 2018-02-27 Genmab A/S Human monoclonal antibodies against cd25
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
JP2010504356A (ja) * 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
PL3440109T3 (pl) 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
GB201712032D0 (en) * 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
SG11202008784RA (en) * 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
US20250257141A1 (en) * 2022-04-26 2025-08-14 Hoffmann-La Roche Inc. Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist

Also Published As

Publication number Publication date
CA3020204A1 (en) 2017-10-12
JP7325959B2 (ja) 2023-08-15
CN109476739A (zh) 2019-03-15
EP3440109A1 (en) 2019-02-13
EP3440109C0 (en) 2025-07-23
WO2017174331A1 (en) 2017-10-12
EP3440109B1 (en) 2025-07-23
RU2759970C2 (ru) 2021-11-19
AU2017247880B2 (en) 2024-07-11
CL2018002828A1 (es) 2019-03-08
AU2017247880A1 (en) 2018-11-15
BR112018070636A2 (pt) 2019-02-05
JP2019513725A (ja) 2019-05-30
CL2019003498A1 (es) 2020-05-29
IL262129B2 (en) 2025-07-01
IL262129A (en) 2018-11-29
RU2018135247A (ru) 2020-05-12
PL3440109T3 (pl) 2025-12-01
IL262129B1 (en) 2025-03-01
ES3046543T3 (en) 2025-12-02
KR20190017735A (ko) 2019-02-20
RU2018135247A3 (es) 2021-01-20
US20190135925A1 (en) 2019-05-09
US20230265200A1 (en) 2023-08-24
KR20220032642A (ko) 2022-03-15

Similar Documents

Publication Publication Date Title
MX2018012319A (es) Anticuerpos biespecificos contra el receptor de fc gamma cd25 para la reduccion de celulas especificas de tumores.
NZ756984A (en) Fc-optimized anti-cd25 for tumour specific cell depletion
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
PH12017501166A1 (en) Antibodies to tight
HK1255161A1 (zh) 用於过继性细胞治疗的工程细胞
UY36289A (es) ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MX382549B (es) Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
PH12016502491A1 (en) Bispecific heterodimeric diabodies and uses thereof
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2015013194A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 humanizado.
NZ728688A (en) Anti-pd-1 antibodies
SG10201901057UA (en) Anti-pd-l1 antibodies
NZ631015A (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2019004940A (es) Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2020002301A (es) Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
NZ747511B2 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion